

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	2590.0050002/EJH/SAC
-------	---	----	---	------------------------	----------------------

801940v1

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/594,177 (U.S. National Phase of PCT/EP04/07529)
				Filing Date	Int'l Filing Date: July 8, 2004
				First Named Inventor	EHLICH, Andreas
				Art Unit	1632
				Examiner Name	To Be Assigned
Sheet	1	of	2	Attorney Docket Number	2590.0050002/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	BRONSTEIN, I., <i>et al.</i> , "Chemiluminescent Reporter Gene Assays: Sensitive Detection of the GUS and SEAP Gene Products," <i>Biotechniques</i> 17:172-174, 176-177, Informa Healthcare USA, Inc. (1994)	
	NPL2	GUAN, K., <i>et al.</i> , "Embryonic Stem Cells <i>in vitro</i> - Prospects for Cell and Developmental Biology, Embryotoxicology and Cell Therapy," <i>ALTEX</i> 16:135-141, Spektrum Akademischer Verlag (1999)	
	NPL3	HUNTER, J.J., <i>et al.</i> , "Ventricular Expression of a MLC-2v-ras Fusion Gene Induces Cardiac Hypertrophy and Selective Diastolic Dysfunction in Transgenic Mice," <i>J. Biol. Chem.</i> 270:23173-23178, The American Society for Biochemistry and Molecular Biology, Inc. (1995)	
	NPL4	KLUG, M.G., <i>et al.</i> , "Genetically Selected Cardiomyocytes from Differentiating Embryonic Stem Cells Form Stable Intercardiac Grafts," <i>J. Clin. Invest.</i> 98:216-224, American Society for Clinical Investigation (1996)	
	NPL5	LIU, H-S., <i>et al.</i> , "Is Green Fluorescent Protein Toxic to the Living Cells?," <i>Biochem. Biophys. Res. Commun.</i> 260:712-717, Academic Press (1999)	
	NPL6	METZGER, J.M., <i>et al.</i> , "Vital Staining of Cardiac Myocytes During Embryonic Stem Cell Cardiogenesis In Vitro," <i>Circ. Res.</i> 78:547-552, Lippincott Williams & Wilkins (1996)	
	NPL7	MÜLLER, M., <i>et al.</i> , "Selection of ventricular-like cardiomyocytes from ES cells in vitro," <i>FASEB J.</i> 14:2540-2548, The Federation of American Society for Experimental Biology (2000)	
	NPL8	ROHWEDEL, J., <i>et al.</i> , "Embryonic stem cells as an <i>in vitro</i> model for mutagenicity, cytotoxicity and embryotoxicity studies; present state and future prospects," <i>Toxicol. In Vitro.</i> 15:741-753, Pergamon Press (2001)	
	NPL9	WOBUS, A.M., <i>et al.</i> , "Retinoic Acid Induces Expression of the Ventricular 2.1 kb Myosin-Light-Chain-2 Promoter During <i>In Vitro</i> Cardiogenesis of Embryonic Stem Cells," <i>Circulation</i> 92 Suppl. I:I114, American Heart Association (1995)	
	NPL10	WOBUS, A.M., <i>et al.</i> , "Retinoic Acid Accelerates Embryonic Stem Cell-Derived Cardiac Differentiation and Enhances Development of Ventricular Cardiomyocytes," <i>J. Mol. Cell Cardiol.</i> 29:1525-1539, Academic Press (1997)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/594,177 (U.S. National Phase of PCT/EP04/07529)
				Filing Date	Int'l Filing Date: July 8, 2004
				First Named Inventor	EHLICH, Andreas
				Art Unit	1632
				Examiner Name	To Be Assigned
Sheet	2	of	2	Attorney Docket Number	2590.0050002/EJH/SAC

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	Office Action for European Patent Application No. 04 740 821.6 (regional phase of PCT/EP2004/007529), dated May 18, 2007, European Patent Office, Munich, Germany	
	NPL12	International Search Report for International Application No. PCT/EP2004/007529, mailed on March 16, 2005, European Patent Office, Rijswijk, Netherlands	
	NPL13	U.S. Application No. 11/547,871, U.S. National Phase of PCT/EP2005/003662, inventors Bohlen, <i>et al.</i> , International Filing Date April 7, 2005, § 371 Date September 28, 2007, NOT YET PUBLISHED	
	NPL14	U.S. Application No. 11/596,262, U.S. National Phase of PCT/EP2005/005087, inventors Bohlen, <i>et al.</i> , International Filing Date May 11, 2005, § 371 Date August 29, 2007, NOT YET PUBLISHED	
	NPL15	International Preliminary Report on Patentability for International Application No. PCT/EP2004/007529, completed on August 26, 2005, European Patent Office, Munich, Germany	

801949v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.